Polycystic ovary syndrome is one of the most common endocrine disorders affecting women of reproductive age, characterized by irregular or absent ovulation, elevated androgens, and polycystic ovarian morphology. Because the hypothalamic-pituitary-ovarian axis behaves differently in these patients, with altered gonadotropin secretion patterns and often exaggerated ovarian sensitivity to hormonal cues, reproductive endocrinologists have debated for decades whether a high baseline LH level helps or harms women undergoing controlled ovarian stimulation. Some earlier hypotheses implicated elevated LH in impaired oocyte quality and reduced implantation, prompting some clinics to suppress LH before treatment. Others argued that LH plays a supportive role in theca cell androgen production, which fuels estradiol synthesis in the granulosa cells that nurture developing follicles. Until now, direct clinical evidence in PCOS patients undergoing modern IVF and intracytoplasmic sperm injection protocols has remained thin.

The research team, led by first authors Jun Liu, Xiaoyu Yu, and Fengjuan Zhang, analyzed records from 162 women with PCOS and 120 controls who all underwent IVF or ICSI followed by embryo transfer at a single reproductive medicine center. To probe whether the starting LH level mattered, the investigators stratified the PCOS patients into high-LH and low-LH groups and then systematically compared their endocrine profiles, ovarian stimulation responses, embryological parameters, endometrial characteristics, and pregnancy outcomes. The ethics committee of Sichuan Provincial Women’s and Children’s Hospital approved the protocol, and all participants provided informed consent, with the study conducted under the Declaration of Helsinki.

The baseline comparisons confirmed the expected metabolic and endocrine signature of PCOS: women with the syndrome had higher body mass index, higher testosterone, and markedly elevated anti-Müllerian hormone, the marker that reflects the enlarged pool of small antral follicles that defines the condition. Yet when it came to the mechanics of stimulation, the two PCOS subgroups diverged in an instructive way. Women in the high-LH group displayed a higher antral follicle count, needed lower total gonadotropin doses to drive multifollicular development, and reached higher estradiol concentrations on the day of the hCG trigger. Together these three signals point in one direction: a higher starting LH level was associated with enhanced ovarian responsiveness, meaning the ovaries of these women answered the stimulation drugs more vigorously and more economically.

Crucially, however, that heightened responsiveness did not translate into better reproductive outcomes. Fertilization rates were statistically indistinguishable between the high- and low-LH PCOS groups, as were embryo quality measures and the proportion of high-quality embryos produced per cycle. The stimulation duration itself was similar across groups, indicating that LH status did not accelerate or delay follicular maturation in any clinically meaningful way. When the investigators tracked the downstream pregnancy endpoints, the pattern held firm: biochemical pregnancy rates, clinical pregnancy rates, and live birth rates showed no significant differences attributable to baseline LH. The hormone that visibly reshaped the stimulation cycle left the bottom line untouched.

To place these subgroup findings in a broader context, the authors applied logistic regression modeling to identify independent predictors of clinical pregnancy across the cohort. The result was striking in what it excluded as much as in what it included. Body mass index and anti-Müllerian hormone emerged as significant independent predictors, while baseline LH failed to reach predictive significance. In practical terms, this means a clinician weighing the prognosis for a PCOS patient about to start an IVF cycle would gain more from noting her weight and her AMH level than from her pre-treatment LH value. The study also flagged a sobering signal on the other side of the pregnancy equation: miscarriage risk was elevated in PCOS patients overall compared with controls, and this risk appeared particularly concentrated in the low-LH subgroup, hinting that insufficient LH activity may be associated with a less favorable early pregnancy environment even if it does not impede conception itself.

What might explain the apparent paradox that LH shapes responsiveness without affecting outcomes? The researchers turned to an animal model for mechanistic insight, establishing a PCOS rat model and examining the ovaries for changes in the expression of the two gonadotropin receptors that orchestrate follicular development: the follicle-stimulating hormone receptor, FSHR, and the luteinizing hormone receptor, LHR. In the granulosa cells, the specialized support cells surrounding each oocyte, the PCOS rats showed a coordinated remodeling of receptor expression, with FSHR decreased and LHR increased. This local shift suggests that under PCOS conditions the ovary recalibrates its sensitivity to the two pituitary hormones, potentially compensating for systemic hormonal disturbances in ways that alter how external stimulation protocols are experienced at the cellular level.

The receptor findings carry implications beyond the laboratory. If granulosa cells in PCOS ovaries downregulate FSHR while upregulating LHR, the conventional assumption that FSH-driven stimulation proceeds through the same molecular machinery in PCOS and non-PCOS ovaries becomes questionable. Elevated local LHR expression could partly explain why high-LH PCOS patients respond so exuberantly to exogenous gonadotropins, achieving robust estradiol rises with lower drug doses. At the same time, the dysregulation of this local signaling network may contribute to the disordered folliculogenesis that characterizes the syndrome, and could interact with the elevated miscarriage risk the study documented, though the authors are careful to present the animal data as suggestive of dysregulated gonadotropin signaling rather than proof of a specific causal chain running from receptor expression to pregnancy loss.

For patients, the clinical takeaway is genuinely liberating. Women with PCOS who discover a high LH value on their pre-treatment blood panel need not fear that this number has doomed their cycle, nor should those with low LH assume their chances are compromised at the outset. The study indicates that baseline LH in PCOS is a marker of ovarian responsiveness, useful perhaps for tailoring gonadotropin starting doses and anticipating hyper-response, but not a determinant of fertilization, implantation, clinical pregnancy, or live birth. Meanwhile, the identification of BMI and AMH as independent predictors reinforces what a growing body of literature has argued: weight management and ovarian reserve assessment deserve central places in fertility counseling for PCOS patients. Elevated AMH, though it reflects the abundant follicle pool that makes PCOS ovaries so responsive, emerged alongside BMI as a predictor of clinical pregnancy, underscoring the complex double-edged role this hormone plays in the syndrome.

As with all retrospective single-center studies, the findings come with caveats that invite future work. The cohort of 282 participants is substantial but retrospective design cannot exclude residual confounding, and stimulation protocols, laboratory conditions, and transfer strategies may vary across centers and eras. Nonetheless, the study’s dual design, combining a well-stratified clinical cohort with mechanistic receptor analysis in an animal model, gives it unusual breadth for the field. By demonstrating that the luteinizing hormone value on a pre-treatment lab slip tells a story about ovarian sensitivity but not about babies, the Chengdu team has helped refocus attention on the factors that truly move the needle for women with PCOS pursuing assisted reproduction, while opening a fresh line of inquiry into how the ovary’s own receptor landscape rewires itself in one of the most common hormonal disorders of our time.

Subject of Research: The effect of basal luteinizing hormone levels on IVF/ICSI-ET outcomes in women with polycystic ovary syndrome

Article Title: Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study

Article References: Liu, J., Yu, X., Zhang, F., Liu, W., Zeng, J., & Wang, L. (2026). Effect of basal luteinizing hormone on IVF/ICSI-ET outcomes in patients with polycystic ovary syndrome: a retrospective study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02603-5

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02603-5

Keywords: polycystic ovary syndrome, luteinizing hormone, IVF, ICSI, embryo transfer, anti-Müllerian hormone, ovarian stimulation, live birth rate, miscarriage risk, granulosa cells, FSHR, LHR

The research team, led by Xiaoju Wan and corresponding author Jun Tan, analyzed records from 3,770 women who underwent their first IVF or intracytoplasmic sperm injection cycle between January 2016 and March 2026. Crucially, the investigators did not study a broad and heterogeneous infertility population. Instead, they restricted enrollment to women with tubal factor infertility, meaning the blockage or damage of the fallopian tubes was the sole identified cause of their inability to conceive, and they required all participants to have normal ovarian reserve as measured by standard hormonal markers. This design choice matters enormously. By removing ovarian reserve impairment and reproductive endocrinopathies such as polycystic ovary syndrome from the equation, the researchers could isolate the question they really wanted to answer: does the metabolic profile of a woman’s body modify how her weight affects the earliest stages of embryonic development?

To answer that question, the team borrowed a stratification concept that has gained traction in cardiology and diabetology but had rarely been applied so rigorously in reproductive medicine. Each woman was classified as either metabolically healthy or metabolically unhealthy based on a composite assessment of blood pressure, glucose metabolism, and blood lipid profiles. The cohort split almost evenly, with 1,849 women in the metabolically healthy group and 1,921 in the metabolically unhealthy group. Within each group, women spanned the full BMI spectrum from underweight through normal weight, overweight, and obesity. This two-by-two architecture, crossing body size categories with metabolic status, allowed the investigators to test formally whether metabolic comorbidities such as hypertension, insulin resistance, or dyslipidemia interact with adiposity to shape reproductive outcomes, or whether the fat tissue itself carries the reproductive consequences.

The embryological results were striking in their consistency. Across both metabolic subgroups, higher BMI was positively associated with oocyte yield, meaning heavier women tended to produce more eggs during ovarian stimulation. The researchers probed this relationship further using mediation analysis, a statistical technique that decomposes an association into direct and indirect pathways. They found that basal follicle-stimulating hormone, a key hormonal signal that typically falls as BMI rises, accounted for roughly 4.7 to 6.3 percent of the association between BMI and oocyte yield. In other words, part of the reason heavier women retrieve more eggs appears to lie in the dampening of FSH signaling, which allows more follicles to be recruited during stimulation. Importantly, this indirect pathway behaved the same way in metabolically healthy and metabolically unhealthy women alike, with no statistically significant difference between the two cohorts.

Where excess weight did exact a measurable toll was at the cellular crossroads of fertilization and embryo development. Among women classified as overweight or obese, the proportion of oocytes that reached the two-pronuclei stage, the earliest microscopic confirmation of successful fertilization, was lower by 3.4 percent in conventional IVF and 3.9 percent in ICSI, the technique in which a single sperm is injected directly into the egg. The same group showed a 3.5 percent reduction in the rate of good-quality blastocyst formation in IVF cycles and a 4.1 percent reduction in the proportion of mature metaphase II oocytes in ICSI cycles. These are modest absolute differences, but they are consistent across multiple endpoints and, notably, they appeared regardless of whether the women were metabolically healthy or unhealthy. The pattern suggests that the developing embryo is sensitive to something about excess adiposity itself, perhaps the inflammatory and endocrine milieu that fat tissue generates, rather than to the classic metabolic diseases that often accompany it.

The underweight category told a more nuanced story. Women with low BMI undergoing ICSI showed an 11.4 percent higher rate of good-quality day three embryos, a substantial relative advantage at this early developmental checkpoint. On the clinical side of the ledger, however, the picture grew quieter. After the researchers applied corrections for multiple comparisons, a statistical safeguard that reduces the risk of false positives when many outcomes are tested simultaneously, no association between BMI and clinical pregnancy, miscarriage, or live birth remained statistically significant. Yet the effect sizes themselves were informative. Underweight women showed a clinically meaningful 3.5 percent reduction in miscarriage rate, while the absolute differences in clinical pregnancy and live birth rates were small, at or below 2.5 percent. The authors are careful to note that the absence of statistical significance does not prove the absence of any effect; it may simply reflect the limits of the sample size for these downstream endpoints.

Perhaps the most consequential finding of the study is what it did not find. Across every outcome examined, from oocyte yield through fertilization, embryo quality, and clinical results, the researchers detected no significant interaction between BMI and metabolic health status. In plain terms, being metabolically healthy did not buffer a woman with obesity against the embryological penalties of excess weight, and being metabolically unhealthy did not worsen those penalties beyond what body size alone predicted. This null interaction, while seemingly a negative result, carries a provocative positive implication: adiposity per se, rather than the hypertension, glucose intolerance, or dyslipidemia that so often travel alongside it, may be the primary factor linking body weight to ART outcomes in tubal factor infertility. The authors appropriately hedge, acknowledging that a lack of statistical interaction does not entirely exclude metabolic modification, but the direction of the evidence points firmly toward the fat tissue itself.

The technical strengths of the study deserve emphasis. By homing in on tubal factor infertility with normal ovarian reserve, the design eliminates two of the most powerful confounders in previous BMI research, since conditions like diminished ovarian reserve and polycystic ovary syndrome both distort ovarian response and correlate with body weight. The large sample of nearly 3,800 first cycles, the decade-long enrollment window, the pre-specified battery of embryological and clinical endpoints, and the formal mediation and interaction analyses together represent a methodological step change from the smaller, heterogeneous cohorts that have fueled decades of contradictory findings. The inclusion of power and effect size analyses further allows readers to judge not just whether associations were significant but how large they plausibly were, an approach that tempers both overstatement and dismissal.

Limitations remain, as they do in any retrospective analysis. The single-center design at a Chinese tertiary hospital may limit generalizability to other populations and clinical protocols. Metabolic health was defined by routinely measured clinical parameters rather than by more sensitive research tools such as insulin clamps or inflammatory biomarkers, so subtle metabolic dysfunction could have been misclassified. The study also cannot capture lifestyle factors, diet composition, or body fat distribution, all of which may modulate reproductive physiology independently of BMI. And because the cohort was restricted to tubal factor infertility with preserved ovarian reserve, the findings may not extend to women whose infertility stems from ovulatory disorders or diminished egg supply, where metabolic factors could play a different and possibly larger role.

For patients and clinicians, the practical message is both sobering and clarifying. Women preparing for IVF who carry excess weight cannot assume that normal blood pressure, normal glucose, and normal lipids will insulate their embryos from the consequences of adiposity, since the embryological penalties observed here appeared in metabolically healthy and unhealthy women alike. Conversely, the small absolute differences in pregnancy and live birth outcomes suggest that weight is one factor among many, not a verdict on fertility potential. The study’s deeper contribution is conceptual: it imports the metabolic health stratification framework into reproductive medicine and demonstrates that the BMI-ART relationship survives, largely unchanged, when the metabolic fog is lifted. If future prospective studies confirm that fat mass itself, through its inflammatory secretions and endocrine activity, is the operative variable, weight management before IVF may need to be reframed not as a metabolic intervention but as a direct reproductive one, with counseling and preconception programs tailored accordingly.

Subject of Research: The influence of body mass index and metabolic health status on assisted reproductive technology outcomes in women with tubal factor infertility

Article Title: Beyond metabolic comorbidity: metabolic health stratification reveals BMI–ART associations in tubal factor infertility

Article References: Wan, X., Yu, M., Wu, X., Huang, Z., & Tan, J. (2026). Beyond metabolic comorbidity: metabolic health stratification reveals BMI–ART associations in tubal factor infertility. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02248-x

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02248-x

Keywords: body mass index, metabolic health, assisted reproductive technology, IVF, ICSI, tubal factor infertility, oocyte yield, embryo quality, blastocyst formation, mediation analysis, obesity, fertility

The drug at the center of the question is propofol, a short-acting agent that has become the workhorse of general anesthesia for oocyte retrieval worldwide. Propofol acts rapidly on the central nervous system by modulating GABA receptors, producing sedation within seconds and clearing quickly once the infusion stops, which makes it ideal for procedures lasting under an hour. But propofol is also lipophilic and biologically active, and laboratory studies have suggested it can cross the follicular barrier and appear in follicular fluid. Animal and in vitro experiments have raised the theoretical possibility that anesthetic exposure around the time of fertilization could perturb calcium signaling, spindle dynamics, or mitochondrial activity in the oocyte, processes that are critical in the hours and days that follow. Whether these laboratory signals translate into any meaningful effect on real human embryos has remained stubbornly unclear.

The research team, led by Xingwu Wu and colleagues, tackled the problem with a tool that only recently became standard in advanced embryology laboratories: time-lapse imaging, or TLI. Conventional embryo assessment relies on brief, discrete snapshots, with embryologists lifting embryos from their incubators once a day to grade them under a microscope. That approach misses nearly everything that matters, because the most informative events of early development, including pronuclear appearance, syngamy, and each successive cell division, unfold in the dark between observations. Time-lapse incubators solve this by photographing each embryo every few minutes without disturbing it, generating a continuous film of development. The resulting timeline of events, known as morphokinetics, gives researchers an exquisitely sensitive readout of embryonic health, and it is precisely the kind of instrument needed to detect subtle delays or disruptions that an anesthetic agent might cause.

Between April and July 2023, the team enrolled 210 infertile women undergoing IVF or intracytoplasmic sperm injection at their center. Of these, 101 received propofol-based general anesthesia during oocyte retrieval, while 109 underwent the procedure without general anesthesia and served as the control group. Because the study was retrospective, the investigators took care to verify that the two groups were comparable before drawing any conclusions, and indeed baseline characteristics and ovarian stimulation outcomes were similar across the board. The number of oocytes retrieved did not differ significantly, nor did the hormonal profiles, laboratory metrics, or stimulation parameters that might otherwise confound a comparison of embryo quality. This methodological grounding matters enormously in anesthesia research, where differences in patient populations can easily masquerade as drug effects.

The primary outcomes were the morphokinetic parameters captured by the time-lapse system, and here the study delivered its most important findings. The researchers tracked the timing of pronuclear appearance, the moment when the two parental genetic packages first become visible as distinct structures within the fertilized egg, as well as the timings of cleavage to the two-, three-, four-, five-, and eight-cell stages, denoted t2 through t8. They also measured the onset of compaction, the start of blastulation, the time to full blastocyst formation, and the timing of blastocyst expansion. Across every one of these landmarks, the embryos of women who had received propofol were statistically indistinguishable from those of women who had not. The developmental clocks of the two groups ticked in unison, hour by hour, from fertilization through the blastocyst stage.

Secondary outcomes told the same story at the level of the laboratory and the clinic. The rate of normal fertilization, defined by the appearance of two pronuclei, was comparable between groups, as was the cleavage rate, the proportion of day-three embryos judged to be of good quality, and the rate at which embryos progressed to blastocysts. When fresh embryos were transferred, clinical pregnancy rates, miscarriage rates, and live birth rates were all similar between the anesthesia and control groups. In other words, the chain of events that begins with an anesthetized egg retrieval and ends with a take-home baby showed no detectable weak links attributable to propofol. For a field in which patients scrutinize every decision for possible harm to their chances, this consistency across endpoints carries real weight.

The technical strength of the study lies in its use of continuous morphokinetic monitoring rather than static morphology grading alone. Static grading can only describe what an embryo looks like at a given moment, whereas morphokinetics reveals how it got there, including subtle timing anomalies such as direct cleavage from one cell to three, prolonged pronuclear fading, or abnormal synchrony between cell divisions, all of which have been associated with poorer implantation potential in prior literature. Had propofol exposure imposed even a modest developmental delay or increased the frequency of atypical cleavage patterns, a time-lapse platform of this kind would be well positioned to detect it. The absence of any such signal, across a battery of timed landmarks, therefore represents a genuinely rigorous form of negative evidence rather than a simple failure to observe gross abnormalities.

As with any retrospective cohort study, the findings come with caveats that the authors and independent readers alike should keep in view. Allocation to anesthesia was not randomized, so residual confounding by indication, meaning systematic differences between patients who chose or were assigned general anesthesia and those who did not, cannot be entirely excluded, even with comparable baseline characteristics. The single-center design, while ensuring uniform laboratory protocols and embryology practices, means the results reflect one institution’s patient population and clinical routines. The sample size of 210 participants, though adequate for detecting moderate differences in morphokinetic timing, may not have been powered to exclude very small effects on rare outcomes such as miscarriage. The authors also note that the study was approved by their institutional ethics committee with written informed consent from all participants, and it was funded by the Natural Science Foundation of Jiangxi Province.

Even with those limitations, the study lands at a consequential moment. Propofol remains the default anesthetic for oocyte retrieval in most fertility centers because it offers rapid onset, swift recovery, and reliable patient comfort during an uncomfortable transvaginal needle procedure, and alternatives such as conscious sedation or paracervical blocks each carry their own trade-offs in efficacy and tolerability. Persistent uncertainty about embryonic effects has left some patients and clinicians to weigh comfort against a feared, but unquantified, reproductive risk. By combining a clinically relevant exposure, a sensitive continuous imaging platform, and a full chain of outcomes from fertilization through live birth, the Nanchang team has provided the kind of reassuring, mechanistically informed data that the field has needed. The message for patients heading into an egg retrieval is straightforward: choosing general anesthesia with propofol to stay comfortable during the procedure does not appear to cost their embryos anything measurable, either in the incubator or in the clinic.

Subject of Research: Effects of propofol general anesthesia during oocyte retrieval on embryo morphokinetics and IVF clinical outcomes

Article Title: Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study

Article References: Wu, X., Zhong, Y., Xia, L., Huang, J., Chen, J., Zhang, Z., Liu, P., Tian, L., Tan, J., Chen, H., Xin, C., Huang, Z., & Zhao, Y. (2026). Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02289-2

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02289-2

Keywords: propofol, general anesthesia, oocyte retrieval, IVF, ICSI, embryo morphokinetics, time-lapse imaging, blastocyst, clinical pregnancy, live birth, fertility treatment, retrospective cohort study

The study, published in the Journal of Ovarian Research, is notable less for introducing a new model than for testing one rigorously. Prediction models in reproductive medicine are abundant, but very few are subjected to what statisticians call external validation, the process of confirming that a tool works not just in the population where it was developed but in entirely new groups of patients treated at different hospitals. Without such validation, a model’s apparent accuracy may be nothing more than a statistical artifact of its original dataset, a phenomenon researchers describe as overfitting.

To address this, a team led by Chang Liu, Huan Zhang and Yili Teng of the Reproductive Medicine Center at the First Affiliated Hospital of Wenzhou Medical University assembled an exceptionally large cohort: 14,702 women aged 35 or younger undergoing their first IVF or ICSI cycle between January 2023 and December 2025. The data came from six reproductive centers across several Chinese provinces, including sites in Shandong, Zhejiang, Guangxi and elsewhere. The researchers validated the existing nomogram, a graphic scoring instrument that converts patient characteristics into a probability, using two complementary strategies. Temporal validation tested the model on later patients at the original development center, while geographic validation tested it across five independent hospitals.

All of the predictors in the model are collected before ovarian stimulation begins, which is precisely what makes the tool clinically actionable. They include the woman’s age, her anti-Müllerian hormone level, her antral follicle count as seen on ultrasound, her baseline follicle-stimulating hormone level, and the ratio of follicle-stimulating hormone to luteinizing hormone. Each of these measures reflects a different facet of what reproductive biologists call the ovarian reserve, the pool of remaining follicles in the ovaries. Anti-Müllerian hormone, secreted by small growing follicles, serves as a chemical census of that pool. The antral follicle count provides a direct visual count of recruitable follicles, while FSH and its ratio to LH capture how hard the pituitary gland must work to drive the ovaries, a signal that rises as ovarian responsiveness declines.

The scale of the problem the model addresses is underscored by the study’s headline finding: across all six centers, the rate of low oocyte retrieval among these young women reached 47.2 percent. In other words, nearly one in two patients who might assume that youth guarantees a bountiful egg harvest in fact ended their first stimulation cycle with a disappointing yield. Low oocyte retrieval matters because the number of eggs retrieved is tightly linked to the number of embryos available for transfer, the chances of success per cycle, and the emotional and financial burden placed on patients who must repeat stimulation or accumulate eggs over multiple attempts.

The validation results were strikingly consistent. Across the six centers, the model’s area under the receiver operating characteristic curve, a standard measure of discrimination that reflects how well a tool separates those who will experience an outcome from those who will not, ranged from 0.800 to 0.888, with an overall value of 0.836 and a 95 percent confidence interval of 0.829 to 0.842. In practical terms, an AUC above 0.8 is generally regarded as good discrimination, meaning that a randomly chosen patient who experiences low oocyte retrieval receives a higher risk score than a randomly chosen patient who does not roughly four times out of five. That level of performance, sustained across hospitals with different patient populations and laboratory practices, is the strongest evidence yet that the underlying biology captured by the five parameters is genuinely generalizable.

Discrimination alone, however, is not enough for a clinical tool. A model must also be well calibrated, meaning that when it predicts, for example, a 30 percent risk of low retrieval, roughly three in ten comparable patients actually experience it. The researchers assessed this using calibration plots and the mean absolute error, a metric that quantifies the average gap between predicted and observed probabilities. The mean absolute error values ranged from just 0.004 to 0.040 across centers, indicating that the nomogram’s predicted probabilities track observed outcomes closely. Such calibration is what allows clinicians to communicate a risk estimate to a patient and trust that the number carries real meaning rather than systematic distortion.

The team also evaluated clinical usefulness through decision curve analysis, a technique that weighs the benefits of correctly identifying high-risk patients against the costs of unnecessary interventions in low-risk ones. Compared with the extreme strategies of treating everyone or treating no one, the nomogram delivered a higher net benefit across a broad range of threshold probabilities, the risk levels at which a clinician and patient would choose to act. The researchers found no statistically significant association between center-level characteristics and model discrimination, though they noted that variation in AUC across sites may still reflect differences in patient characteristics, a reminder that even validated tools perform within the texture of local populations.

For patients and clinicians, the practical implications are considerable. A woman identified as high risk before stimulation could, in principle, be counseled more realistically about her first cycle, offered an individualized stimulation protocol with adjusted gonadotropin dosing, or prepared for the possibility of a dual-ovulation or multiple-cycle approach to accumulate eggs. Low oocyte retrieval in young patients can signal an occult diminished ovarian reserve or unexpected hyporesponsiveness that standard screening sometimes misses, and early identification turns a cycle-ending surprise into a manageable planning problem. Because every input to the nomogram is already part of routine pretreatment workup in IVF clinics worldwide, implementing the tool requires no new tests, only a calculation.

The study was approved by the institutional review board of the First Affiliated Hospital of Wenzhou Medical University and conducted in accordance with the Declaration of Helsinki, with informed consent waived given its retrospective design. Funded by the Wenzhou Municipal Science and Technology Bureau, the work arrives amid a broader movement in reproductive medicine toward pretreatment risk stratification, in which statistical and machine-learning models compress thousands of patient records into instruments usable at the bedside. This nomogram, now tested across six hospitals and nearly fifteen thousand patients, offers one of the clearest demonstrations that such tools can travel well beyond their birthplace. For the roughly half of young IVF patients who would otherwise be blindsided by a poor egg retrieval, that portability may prove the study’s most valuable result, turning a moment of disappointment into an opportunity for foresight.

Subject of Research: External validation of a pretreatment prediction nomogram for low oocyte retrieval in young women undergoing IVF/ICSI

Article Title: Prediction of low oocyte retrieval in young women undergoing IVF/ICSI: a multicenter external validation study

Article References: Liu, C., Zhang, H., Yang, H., Sun, Z., Zhu, Q., Zhang, S., Lv, Y., Fu, X., Dai, C., & Teng, Y. (2026). Prediction of low oocyte retrieval in young women undergoing IVF/ICSI: a multicenter external validation study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02266-9

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02266-9

Keywords: IVF, ICSI, low oocyte retrieval, ovarian reserve, anti-Müllerian hormone, antral follicle count, nomogram, predictive model, multicenter validation, reproductive medicine, fertility treatment, ovarian stimulation